UCB's full-year results 'confirm position of strength'

27 February 2015

The 2014 full-year financial results from Belgian drugmaker UCB (Euronext Brussels: UCB) “confirmed the position of strength” of the company, according to new chief executive Jean-Christophe Tellier.

UCB reported revenue of 3.34 billion euros ($3.74 billion), an increase of 8% at constant currencies on 2013. Net sales stood at 2.94 billion euros, up 6% on last year’s figures. The revenue was in line with the average of estimates in Thomson Reuters StarMine, but fell below expectations for profit, and UCB’s shares fell 3.2% to 67.40 euros.

Operating profit, the company’s earnings before interest and tax, was 379 million euros, up more than a third on last year’s 297 million euros. Earnings per share were up 46% on 2013, now at 1.69 euros, up from 1.24 euros last year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK